

## PHARMACY POLICY STATEMENT

### Arkansas PASSE

DRUG NAME	Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)
BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
COVERAGE REQUIREMENTS	Prior Authorization Required (Preferred Product) QUANTITY LIMIT— 84-count tablet carton for 28 days
LIST OF DIAGNOSES CONSIDERED <b>NOT</b> MEDICALLY NECESSARY	<a href="#">Click Here</a>

Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) will only be considered for coverage under the **pharmacy** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

### CYSTIC FIBROSIS

For **initial** authorization:

1. Member is 12 years old or older; AND
2. Member has a diagnosis of cystic fibrosis; AND
3. Member has had genetic testing documented in chart notes with at least one F508del mutation in the CFTR gene: OR
4. Member has at least one of the following mutations in the CFTR gene: 3141del9, E822K, G1069R, L967S, R117L, S912L, 546insCTA, F191V, G1244E, L997F, R117P, S945L, A46D, F311del, G1249R, L1077P, R170H, S977F, A120T, F311L, G1349D, L1324P, R258G, S1159F, A234D, F508C, H139R, L1335P, R334L, S1159P, A349V, F508C;S1251N, H199Y, L1480P, R334Q, S1251N, A455E, F508del, H939R, M152V, R347H, S1255P, A554E, F575Y, H1054D, M265R, R347L, T338I, A1006E, F1016S, H1085P, M952I, R347P, T1036N, A1067T, F1052V, H1085R, M952T, R352Q, T1053I, D110E, F1074L, H1375P, M1101K, R352W, V201M, D110H, F1099L, I148T, P5L, R553Q, V232D, D192G, G27R, I175V, P67L, R668C, V456A, D443Y, G85E, I336K, P205S, R751L, V456F, D443Y;G576A;R668C, G126D, I502T, P574H, R792G, V562I, D579G, G178E, I601F, Q98R, R933G, V754M, D614G, G178R, I618T, Q237E, R1066H, V1153E, D836Y, G194R, I807M, Q237H, R1070Q, V1240G, D924N, G194V, I980K, Q359R, R1070W, V1293G, D979V, G314E, I1027T, Q1291R, R1162L, W361R, D1152H, G463V, I1139V, R31L, R1283M, W1098C, D1270N, G480C, I1269N, R74Q, R1283S, W1282R, E56K, G551D, I1366N, R74W, S13F, Y109N, E60K, G551S, K1060T, R74W;D1270N, S341P, Y161D, E92K, G576A, L15P, R74W;V201M, S364P, Y161S, E116K, G576A;R668C, L165S, R74W;V201M;D1270N, S492F, Y563N, E193K, G622D, L206W, R75Q, S549N, Y1014C, E403D, G628R, L320V, R117C, S549R, Y1032C, E474K, G970D, L346P, R117G, S589N, E588V, G1061R, L453S, R117H, S737F.
5. **Dosage allowed:** Morning dose: two elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg tablets. Evening dose: one ivacaftor 150 mg tablet. Morning and evening dose should be taken approximately 12 hours apart

***If member meets all the requirements listed above, the medication will be approved for 3 months.***

For **reauthorization**:

1. Member must be in compliance with all other initial criteria; AND
2. Member's adherence to medication is confirmed by claims history; AND
3. Chart notes submitted with any of the following:
  - a) Improved FEV1 and/or other lung function tests;
  - b) Improvement in sweat chloride;
  - c) Decrease in pulmonary exacerbations;
  - d) Decrease in pulmonary infections;
  - e) Increase in weight-gain;
  - f) Decrease in hospitalizations.

***If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.***

**CareSource considers Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) not medically necessary for the treatment of diseases that are not listed in this document.**

DATE	ACTION/DESCRIPTION
11/12/2019	New policy for Trikafta created.
12/31/2020	New approved FDA mutations included. Diagnosis of cystic fibrosis added to initial criteria.
12/22/2021	Removed prescriber specialty requirement.

References:

1. Trikafta [prescribing information]. Boston, MA: Vertex Pharmaceuticals Inc; December, 2020.
2. National Guideline Clearinghouse (NGC). Guideline summary: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. Available: <https://www.atsjournals.org/doi/full/10.1164/rccm.201207-1160OE>.

Effective date: 01/01/2022

Revised date: 12/22/2021